Inve India ▾

Sanjivani Paranteral share price & results

Sanjivani Paranteral Ltd.· Healthcare

Results to
Jun 2026
Latest analysed call
Q4 FY26
Ownership as of
Jun 2026

Mumbai-based pharma manufacturer of injectables (ampoules, vials, IV fluids), tablets/capsules and nutraceuticals, with CDMO contract manufacturing and exports to 25+ countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue19.5 ₹ crore+8.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin17.5 %+2.7 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit2.3 ₹ crore+32.9% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity17.30 %−8.8 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-14.82 %+10.8 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)4.28 %−30.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

1 of 5 judged targets kept · 7 open · verdicts reflect calls analysed to Q4 FY26.

Sanjivani Paranteral Ltd. management guidance track record on Inve: 12 targets tracked across analysed earnings calls (1 achieved, 4 missed, 7 open).

TargetOriginal wordingSaidLatest callVerdict
Pune JV Commercial ProductionCommercial production in this first quarter (Q1 FY26)
Call transcript, Q4 FY25 · 27 May 2025		Q4 FY25Q4 FY26:Ramp-up continues, revenue grew to INR 2.7 cr in Q4 FY26.
Call transcript, Q4 FY26 · 15 May 2026		Achieved*
Pune JV RevenueINR 75-80 crores of top line from this plant in the first year
Call transcript, Q1 FY26 · 12 Aug 2025		Q1 FY26Q4 FY26:Achieved INR 3.9 cr in FY26 (Q3+Q4) vs original target of INR 75-80 cr for the first year (FY26).
Call transcript, Q4 FY26 · 15 May 2026		Missed
EBITDA Margin19%-20% that will be remaining
Call transcript, Q3 FY25 · 11 Feb 2025		Q3 FY25Q4 FY26:Guided 15.5-16.5% for base business going ahead.
Call transcript, Q4 FY26 · 15 May 2026		Revised Down

Source: Inve Guidance Tracker for Sanjivani Paranteral Ltd. · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Sanjivani Paranteral Ltd.'s 12 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 9 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹168.35 +13.21% · +₹19.65

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −15.6% 1Y

₹150₹200Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 19 Nov 2025Q3 FY26 — 16 Feb 2026Q4 FY26 — 15 May 2026

1Y: ₹199.4 on 24 Oct 2025 → ₹168.35. High ₹239.65 (7 Jan 2026), low ₹129.3 (20 May 2026).

Previous close
₹148.7
Market cap
₹167 Cr
52-week range
₹129.3 – ₹239.65
One year
−15.95%
Price to earnings (TTM to Jun 2026)
22.39×
Return on equity (TTM to Jun 2026)
17.30%

Overview

Symbol
NSE:SANJIVIN
Exchange
NSE
Currency
INR

What Sanjivani Paranteral Ltd. does

Based on the company's own presentations, annual report and earnings calls.

Sanjivani Paranteral Limited manufactures and distributes parenteral (injectable) and oral solid pharmaceutical formulations across therapeutic areas including CNS, CVS, antibiotics, gastroenterological, anti-diabetic and anti-allergic. It operates WHO-GMP/DIGEMID/DDA-certified plants at Navi Mumbai and Dehradun, an IV-fluid infusion plant in Pune (SPL Infusion Private Limited) and a joint-venture manufacturing plant in Prague, Czech Republic (with Alevia HealthCare S.R.O.). Alongside its own branded formulations, the company runs a CDMO (contract development and manufacturing) business for third-party clients in injectables, orals and nutraceuticals, and has recently added a nutraceuticals product line.

Segments

  • Injectables
  • Orals
  • Nutraceuticals
  • CDMO
Manufacturing facilities
2 WHO-GMP/DIGEMID/DDA-certified plants (Navi Mumbai & Dehradun), plus an IV-fluid plant in Pune (SPL Infusion Pvt Ltd) and a JV plant in Prague, Czech Republic (Alevia HealthCare)
Annual tablet capacity
720 million tablets/year
Annual Beta-Lactam capsule capacity
180 million capsules/year
Annual Beta-Lactam tablet capacity
120 million tablets/year
Annual ampoule capacity
84 million ampoules/year
Annual capsule capacity
72 million capsules/year
Founded 1994Headquarters Mumbai, MaharashtraEmployees 40 (FY25) Company website

How the price took the results

close before → close after

Q4 FY26
−6.6%
15 May
Q3 FY26
−1.4%
16 Feb
Q2 FY26
+3.0%
19 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Sanjivani Paranteral Ltd.

Free account: one company. Everything above stays public.

Write why you follow Sanjivani Paranteral Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Sanjivani Paranteral Ltd.

Guides on how to read this kind of business and the numbers that matter.